Moss 15.08.19
Gentian Diagnostics AS announces its results for the second quarter and first half of 2019.
The highlights include:
- 16 % growth in sales revenue in 2Q19 compared to 2Q18
- Total sales revenues of MNOK 10.2 in 2Q19, up from MNOK 8.8 in 2Q18
- FDA 510(k) clearance for the BÜHLMANN fCAL® turbo and with this access to the US market
- In July, Beckman Coulter, one of the top 5 global diagnostics companies, and Gentian have prolongated the trusted partnership agreement by another 6 years
- In August, Gentian announced the sales channel agreement for fCAL® turbo between Roche Diagnostics and Gentian’s sales partner Bühlmann Laboratories AG
Please find the report and results presentation enclosed:
GDAS 2019 1H interim report
GDAS 2019 1H interim presentation
For further information, please contact:
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525
MeldingsID: 482926
UtstederID: GENT-ME
Instrument: GENT-ME
Marked: Merkur Market
Kategori: HALVÅRSRAPPORTER OG REVISJONSBERETNINGER / UTTALELSER OM FORENKLET REVISORKONTROLL